Insider Trading June 15, 2026 10:31 PM

Dentsply Sirona Director Brian Gladden Executes $100K Share Purchase Amid Valuation Signals

Executive acquisition occurs as dental equipment maker trades near 52-week lows, with recent earnings showing revenue beats but EPS misses

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
XRAY

Brian T. Gladden, a director at Dentsply Sirona Inc. (NASDAQ:XRAY), completed a common stock acquisition on June 15, 2026, totaling approximately $99,999. The transaction involved the purchase of 9,985.022 shares across multiple executions priced between $10.015 and $10.0156 per share. This acquisition brings Gladden's direct holdings to 61,848.544 shares. The purchase coincides with the stock trading near its 52-week low of $9.40, representing a 34% decline over the past year. Market analysis suggests the stock may be undervalued at current levels, with the company maintaining a 6.31% dividend yield after 32 consecutive years of dividend payments. Recent financial results for the first quarter of 2026 showed Dentsply Sirona exceeding revenue expectations by generating $880 million against forecasts of $842.58 million, a 4.44% surprise. However, earnings per share fell to $0.27, missing the expected $0.28. Needham maintained a Hold rating, citing execution risks despite the revenue beat. The company also announced an expanded distribution partnership with Nashville Dental beginning in August 2026, covering a nine-state territory for connected technology solutions including CEREC and Primescan systems.

Dentsply Sirona Director Brian Gladden Executes $100K Share Purchase Amid Valuation Signals
XRAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Brian Gladden purchased 9,985.022 shares worth $99,999 on June 15, 2026, bringing direct holdings to 61,848.544 shares.
  • Dentsply Sirona trades near its 52-week low of $9.40, down 34% over the past year, with analysis suggesting potential undervaluation.
  • First-quarter 2026 revenue of $880 million exceeded expectations by 4.44%, but EPS of $0.27 missed forecasts of $0.28.

Director Brian T. Gladden has executed a significant common stock acquisition at Dentsply Sirona Inc. (NASDAQ:XRAY), purchasing shares worth approximately $99,999 on June 15, 2026. The transaction involved the acquisition of 9,985.022 shares across multiple executions, with prices ranging from $10.015 to $10.0156 per share. Following this purchase, Gladden's direct holdings in the dental equipment and supplies company total 61,848.544 shares.

The acquisition occurs as Dentsply Sirona trades near its 52-week low of $9.40, reflecting a 34% decline over the past year. Market analysis indicates the stock may be undervalued at current levels, with the company maintaining a 6.31% dividend yield after 32 consecutive years of dividend payments. This positions Dentsply Sirona among platforms identifying potentially undervalued equities.

Recent financial performance presents a mixed picture for the dental equipment manufacturer. First-quarter 2026 results showed revenue exceeding expectations at $880 million, surpassing forecasts of $842.58 million by 4.44%. However, earnings per share fell short of projections at $0.27 versus the expected $0.28. Needham maintained a Hold rating, citing execution risks despite the favorable revenue outcome.

In strategic developments, Dentsply Sirona announced an expanded distribution partnership with Nashville Dental beginning in August 2026. The agreement covers a nine-state territory and includes connected technology solutions such as the CEREC system and Primescan intraoral scanners. This expansion reflects ongoing strategic initiatives within the dental technology sector.

Current stock trading data shows Dentsply Sirona at $10.14, representing a 0.50% increase following market close. After-hours trading indicates further movement to $10.24, up 0.99%. The stock has experienced volatility, with the 52-week low of $9.40 highlighting recent downward pressure.

Investors analyzing Dentsply Sirona may consider the director's share acquisition alongside the company's valuation metrics and dividend history. The 32-year dividend track record and current 6.31% yield provide income characteristics, while the stock's proximity to its 52-week low raises questions about valuation positioning. The mixed earnings results and execution risks noted by analysts suggest continued monitoring of operational performance.

Risks

  • Needham cites execution risks despite revenue beats, indicating potential operational challenges in the dental equipment sector.
  • Stock trading near 52-week lows suggests market uncertainty and valuation pressure in the dental technology market.
  • Mixed earnings results with EPS misses may impact investor confidence in the company's financial performance.

More from Insider Trading

ATN International Insider Activity: Cornelius B. Prior Jr. Executes $2.28M Stock Sale Amid Strategic Shifts Jun 15, 2026 Chegg CEO Daniel Rosensweig's Shares Withheld for Tax Obligations Jun 15, 2026 Mobix Labs President and CFO Samini Offloads Shares Amid Strategic Expansion Jun 15, 2026 Corvel CEO Offloads 500 Shares Amid Undervaluation Signals and Q4 Growth Jun 15, 2026 Fold Holdings Insider Purchase Highlights Director Confidence Amid Operational Headwinds Jun 15, 2026